Overweight/Obesity Up Incidence of Hand, Hip, Knee Osteoarthritis

This article originally appeared here.
Share this content:
Overweight/Obesity Up Incidence of Hand, Hip, Knee Osteoarthritis
Overweight/Obesity Up Incidence of Hand, Hip, Knee Osteoarthritis

WEDNESDAY, Aug. 3, 2016 (HealthDay News) -- The incidence of hand, hip, and knee osteoarthritis (OA) increases with overweight and obesity, particularly in the knee, according to a study published in the August issue of Arthritis & Rheumatology.

Carlen Reyes, M.D., Ph.D., from Universitat Autònoma de Barcelona in Spain, and colleagues conducted a population-based cohort study using primary care records for subjects aged ≥40 years who were without a diagnosis of OA on Jan. 1, 2006, and had body mass index (BMI) data available. A total of 1,764,061 subjects were observed for a median follow-up of 4.45 years.

The researchers found that the incidence rates of knee, hip, and hand OA were 3.7, 1.7, and 2.6 per 1,000 person-years, respectively, for subjects in the normal-weight category, and 19.5, 3.8, and 4.0, respectively, for those with grade II obesity. Being overweight or obese versus normal weight increased the risk of OA at all three joint sites, especially at the knee. The risk of knee OA increased two-, 3.1-, and 4.7-fold with a status of overweight, grade I obesity, and grade II obesity, respectively.

"Being overweight or obese increases the risk of hand, hip, and knee OA, with the greatest risk in the knee, and this occurs on a dose-response gradient of increasing BMI," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »